Loeillot Olivier sold $2.5M of RGEN

Loeillot Olivier (Chief Executive Officer) sold 12,946 shares of REPLIGEN CORP (RGEN) at $190.00 ($2.46M total) across 2 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Sep 25, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
high confidence
Mentioned
$RGEN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishMed
01

Why it matters

The sale reduces insider ownership, potentially influencing investor perception.

02

Market read

Insider sale may trigger short-term price decline; traders may consider adjusting positions.

03

What to watch

CEO may be diversifying portfolio; no immediate operational concerns disclosed.

Relevance 5/10Novelty 6/10Timing: post-market 2026-09-24

Background

Form 4 filing reports insider transactions; investors monitor for signals.

Company-level read

Ticker impact

$RGENBearishHigh confidence
Context

CEO Loeillot Olivier sold 12,946 shares for $2.46M via a 10b5-1 plan, reducing his stake to 48,369 shares.

Expected impact

Short-term downward pressure expected.

Evidence & confidence

Insider sale by CEO indicates possible lack of confidence; size relative to holdings is material.

Market effects

May affect biotech/healthcare sector sentiment as insider sales can be viewed broadly.

US market focus; limited regional effect.

Low global relevance.

Counterpoint

Sale could be routine 10b5-1 execution, not a bearish signal.

Key entities

  • Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

  • Repligen Corp

    Biopharmaceutical company listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.